Dr. Sborov is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1950 Circle of Hope Dr
Salt Lake City, UT 84112Phone+1 801-213-3800Fax+1 801-715-8228
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
University of Utah HealthResidency, Internal Medicine, 2009 - 2012
American University of the Caribbean School of MedicineClass of 2009
Certifications & Licensure
MT State Medical License 2022 - 2026
UT State Medical License 2010 - 2026
CO State Medical License 2022 - 2025
ID State Medical License 2022 - 2025
NV State Medical License 2023 - 2025
WY State Medical License 2022 - 2025
OH State Medical License 2012 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma Start of enrollment: 2021 May 21
Publications & Presentations
PubMed
- Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.Ada Alice Dona, Theophilus Tandoh, Lokesh Nigam, Mahmoud Singer, Enrico Caserta
Journal of Hematology & Oncology. 2025-01-20 - 2 citationsDaratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.Ashraf Badros, Laahn Foster, Larry D Anderson Jr, Chakra P Chaulagain, Erin Pettijohn
Blood. 2025-01-16 - 5 citationsSafety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.Surbhi Sidana, Krina K Patel, Lauren C Peres, Radhika Bansal, Mehmet H Kocoglu
Blood. 2025-01-02
Abstracts/Posters
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Douglas W. Sborov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple MyelomaDouglas W. Sborov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Quad Combination for Myeloma Brings PFS AdvantageAugust 29th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
